Loading
Treatment is often chosen from a biopsy taken years earlier from the original tumour. The spread disease may now look different. Test it again before switching drugs.
Receptor and biomarker discordance between primary and metastasis is well documented (oestrogen receptor, HER2, PD-L1, and actionable alterations). Yet most line changes rely on archival tissue. The proposal is a payer-backed policy that a contemporaneous biopsy or validated liquid biopsy is offered before each line change in metastatic disease, with a registry to quantify how often the result changes therapy.
Shares Tumour heterogeneity and clonal evolution, Acquired resistance to every therapy, Liquid biopsy (ctDNA), Non-small-cell lung cancer.
Shares Tumour heterogeneity and clonal evolution, Acquired resistance to every therapy, Comprehensive genomic profiling, Liquid biopsy (ctDNA).
Shares Tumour heterogeneity and clonal evolution, Acquired resistance to every therapy, Comprehensive genomic profiling, Non-small-cell lung cancer.
Shares Acquired resistance to every therapy, Comprehensive genomic profiling, Liquid biopsy (ctDNA).
Shares Tumour heterogeneity and clonal evolution, Acquired resistance to every therapy, Non-small-cell lung cancer.
Shares Tumour heterogeneity and clonal evolution, Acquired resistance to every therapy, Liquid biopsy (ctDNA), Non-small-cell lung cancer.
Shares Acquired resistance to every therapy, Comprehensive genomic profiling, Liquid biopsy (ctDNA).
Shares HER2-low and HER2-ultralow, Histopathology & immunohistochemistry, HR-positive / HER2-negative breast cancer.